Le Lézard
Classified in: Health, Science and technology
Subjects: AWD, TRI, FVT

Oncotarget awards grants to four biomedical researchers at Frontiers in Cancer Science

ORCHARD PARK, N.Y., Dec. 7, 2017 /PRNewswire/ -- Oncotarget, the world's largest oncology peer-reviewed research publication, awarded travel grants enabling four biomedical researchers to attend November's Frontiers in Cancer Science 2017 (FCS 2017) conference in Singapore. The travel sponsorship encourages the discussion of cancer discoveries in support of Oncotarget's commitment to maximizing the circulation of scientific research.

"We're dedicated to the wide dissemination of scientific advances to improve understanding and spur future discoveries," said Mikhail Blagosklonny, Oncotarget's editor-in-chief. "The Frontiers in Cancer Science meeting brings together top cancer experts from around the globe and as travel sponsor, Oncotarget is proud to have provided the opportunity for new and groundbreaking research from four international institutions to be shared at the meeting."

The sponsored researchers presented studies ranging from assessing the impact of drug treatments on kidney cancer to characterizing the chemoresistance of asbestos-related tumors.  The researchers and their presentations are as follows:

The FCS 2017 conference, which was held November 6 ? 8th, was hosted by seven major research institutes: Cancer Science Institute of Singapore, Duke-NUS Medical School, Genome Institute of Singapore, Institute of Molecular and Cell Biology and Lee Kong Chian School of Medicine.

For more biomedical research in oncology and related areas such as immunology and microbiology, the latest issue of Oncotarget is available at http://www.impactjournals.com/oncotarget.

About Oncotarget

Oncotarget is a twice-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology and publishing sub-sections on topics beyond oncology such as Aging, Immunology and Microbiology, Autophagy, Pathology and Chromosomes and more. Oncotarget is published by Rapamycin Press, the publishing division of Impact Journals LLC.

Media Contact Information:

Ryan James Jessup
Rapamycin Press


SOURCE Oncotarget

These press releases may also interest you

at 07:03
Emerald Health Therapeutics, Inc. (Emerald) has signed a definitive agreement  ("Agreement") to acquire the remaining shares of Northern Vine Canada Inc. (Northern Vine), owned by Abattis Bioceuticals Corp. (Abattis) , for $2 million in cash and...

at 07:00
Barcotm Uniforms today announced that its globally popular Grey's Anatomytm scrub collection has expanded its product line with new tops and bottoms for men and women that now incorporate spandex-stretch, providing unrivaled comfort and flexibility...

at 07:00
According to a new report published by Allied Market Research, titled, "Endoscope + Radiofrequency Ablation (RFA) Market by Application: Global Opportunity Analysis and Industry Forecast, 2017-2025," the global endoscope + radiofrequency ablation...

at 07:00
Concordia International Corp. ("Concordia" or the "Company") , an international specialty pharmaceutical company focused on becoming a leader in European specialty, off-patent medicines, today announced that as a result of the Company's decision not...

at 07:00
BELLUS Health Inc. ("BELLUS Health" or the "Company"), a biopharmaceutical development company advancing novel therapeutics for conditions with high unmet medical need, today announced that the Japan Patent Office has issued a decision to grant...

at 06:45
The U.S. label for Eli Lilly and Company's once-weekly Trulicity® (dulaglutide) is updated to show the medicine's safety and efficacy in people with type 2 diabetes who have moderate to severe chronic kidney disease (CKD). The label now includes...

News published on 7 december 2017 at 14:36 and distributed by: